The Science Behind BPC-157
What the published research actually says — including what we know, what we don't, and why we believe veterinary peptide therapy deserves serious attention.
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide fragment of a gastroprotective protein found naturally in human gastric juice. First isolated and studied in the early 1990s by researchers at the University of Zagreb, it has since become one of the most extensively researched peptides in regenerative medicine.
Unlike traditional pharmaceuticals that target a single pathway, BPC-157 works through multiple mechanisms — promoting blood vessel formation, modulating the nitric oxide system, upregulating growth factors, reducing inflammation, and accelerating tissue repair across tendons, ligaments, muscles, the GI tract, bone, and nerve tissue.
With over 100 peer-reviewed studies published across multiple species, BPC-157 has demonstrated a remarkably consistent safety profile and broad therapeutic potential. Most research has been conducted in rodent models, but the 2022 beagle pharmacokinetic study (He et al.) provides the strongest dog-specific evidence to date — showing that dogs actually absorb BPC-157 significantly better than rats.
Mechanism of Action
BPC-157 doesn't just mask symptoms. It works at the cellular level through multiple pathways to support the body's natural healing processes.
Angiogenesis
BPC-157 promotes the formation of new blood vessels (angiogenesis), improving blood flow to damaged tissues. This accelerates delivery of nutrients and oxygen needed for repair — particularly relevant for aging joints with compromised circulation.
Anti-Inflammatory Pathways
The peptide modulates inflammatory pathways, reducing chronic inflammation in joints and connective tissue. Unlike NSAIDs, which block inflammation systemically, BPC-157 appears to modulate the inflammatory response without the liver and kidney risks associated with long-term NSAID use.
Growth Factor Upregulation
BPC-157 upregulates key growth factors including EGF (epidermal growth factor), VEGF (vascular endothelial growth factor), and others involved in tissue repair. This supports healing of tendons, ligaments, muscles, and the GI tract by enhancing collagen synthesis and cellular regeneration.
Nitric Oxide System Modulation
BPC-157 interacts with the nitric oxide (NO) system, which plays a central role in vascular function, inflammation, and nerve signaling. This NO modulation may contribute to its broad therapeutic effects across multiple tissue types.
Unique Acid Stability
Unlike most peptides, BPC-157 is remarkably stable in gastric acid — it was originally isolated from gastric juice. This unique property means it survives stomach acid intact, making oral dosing viable. Most therapeutic peptides are destroyed by digestion and require injection.
Key Research
The evidence base for BPC-157 spans over 100 published studies. These are the most relevant to veterinary applications.
He et al. 2022 — Beagle Pharmacokinetic Study
Published in Frontiers in Pharmacology · DOI: 10.3389/fphar.2022.1026182
The strongest dog-specific evidence for BPC-157. This study evaluated the pharmacokinetics of BPC-157 in beagle dogs at three intramuscular doses (6, 30, and 150 mcg/kg) and one intravenous dose (6 mcg/kg).
Key Findings:
- •45–51% intramuscular bioavailability in dogs — significantly higher than the 14–19% observed in rats (dogs absorb 2.5–3x more)
- •Half-life under 30 minutes with peak absorption (Tmax) at approximately 6–8 minutes after IM injection
- •Linear pharmacokinetics across all doses tested
- •No accumulation observed with 7-day repeat dosing
Why it matters: This is the first study to establish absorption, distribution, and bioavailability data specifically in a canine model. The high bioavailability in dogs compared to rats suggests dogs may be particularly good candidates for BPC-157 therapy.
Xu et al. 2020 — Comprehensive Safety Assessment
Published in Regulatory Toxicology and Pharmacology · View Study
A systematic safety evaluation of BPC-157 across multiple species — mice, rats, rabbits, and dogs.
Key Findings:
- •No deaths at any dose in any species tested
- •No toxic dose identified — researchers could not establish a lethal dose
- •No genotoxicity (no DNA damage)
- •No embryo-fetal toxicity
- •Only finding: decreased creatinine at 2,000 mcg/kg (333x the therapeutic dose) — which self-resolved within 2 weeks
- •Greater than 300x safety margin between therapeutic dose and any observed effect
Why it matters: An exceptional safety profile. The inability to identify a toxic dose, combined with no adverse events across four species, provides strong preclinical safety data.
Seiwerth et al. 2018 — Comprehensive Mechanism Review
Published in Current Pharmaceutical Design
A thorough review of BPC-157's mechanisms of action across 25+ years of research, covering its effects on multiple organ systems and tissue types.
Key Findings:
- •Documented effects on angiogenesis, NO system, growth factor expression, and anti-inflammatory pathways
- •Healing effects demonstrated across tendons, ligaments, muscles, bone, GI tract, nerves, and corneal tissue
- •Unique gastroprotective properties — BPC-157 protects and heals the GI lining
Why it matters: Establishes BPC-157 as a multi-system peptide with broad therapeutic potential, not a single-pathway drug.
Chang et al. 2011 — Tendon Healing
Published in Journal of Applied Physiology
Evaluated BPC-157's effects on tendon-to-bone healing in a rat model.
Key Findings:
- •Accelerated tendon healing with improved biomechanical strength
- •Enhanced collagen organization at the repair site
Why it matters: Directly relevant to senior dogs with tendon injuries or age-related tendon degeneration.
Kang et al. 2012 — Bone Healing Properties
Published in Journal of Bone and Mineral Metabolism
Studied BPC-157's effects on bone healing in a segmental bone defect model.
Key Findings:
- •Promoted new bone formation and improved fracture healing
- •Enhanced osteogenic activity at the defect site
Why it matters: Suggests BPC-157 may support bone health in aging dogs — relevant for osteoarthritis and fracture recovery.
Cesarec et al. 2013 — Muscle Healing
Published in Current Pharmaceutical Design
Examined BPC-157's effects on crush-injured muscle tissue.
Key Findings:
- •Accelerated muscle fiber repair and regeneration
- •Reduced inflammation at the injury site
Why it matters: Relevant for senior dogs experiencing muscle wasting (sarcopenia) and soft tissue injuries.
Sikiric et al. — 25+ Years of Original Research
Published in Multiple publications
The original BPC-157 research group, led by Predrag Sikiric at the University of Zagreb, has published extensively on BPC-157 since the early 1990s. Their body of work spans tissue repair, organ protection, and systemic healing effects.
Key Findings:
- •Demonstrated healing effects across virtually every tissue type studied
- •Established the peptide's unique acid stability and gastric origin
- •Proposed BPC-157 as a 'stable gastric pentadecapeptide' with systemic protective properties
Why it matters: The foundational research that everything else builds on. Over two decades of consistent, positive findings across multiple labs and models.
What We Don't Know Yet
Transparency matters. Here's an honest look at the current limitations of BPC-157 research.
No FDA-Approved Indication
BPC-157 is not FDA-approved for any use — human or veterinary. There are no completed Phase III clinical trials. Our treatments are provided through veterinary compounding under a licensed vet's prescription, which is the legal and proper way to access compounded medications.
Most Studies Are in Rodent Models
The majority of the 100+ published studies were conducted in rats and mice. While the results have been remarkably consistent across models, rodent studies don't always translate directly to dogs or humans. The He et al. 2022 beagle study is the strongest dog-specific evidence available.
More Veterinary Clinical Trials Are Needed
We need more controlled clinical studies in dogs — measuring real outcomes like mobility, pain scores, and quality of life over time. This is one of the reasons Long Companion Labs tracks outcomes for every patient: to build the real-world evidence base that the field needs.
Mechanism Not Fully Understood
While BPC-157's effects have been documented extensively, the precise molecular mechanisms are still being studied. We know it works through multiple pathways (angiogenesis, NO system, growth factors), but the complete picture is still emerging.
Why Peptide Therapy for Dogs?
Integrative medicine has transformed human healthcare. Peptide therapy, in particular, has become a cornerstone of longevity and regenerative medicine for people — prescribed by physicians to support tissue repair, reduce inflammation, and improve quality of life.
Dogs deserve the same standard of care. Senior dogs face many of the same age-related challenges humans do: joint degeneration, chronic inflammation, reduced mobility, and declining vitality. Traditional veterinary options — NSAIDs, glucosamine supplements, or simply accepting "it's just age" — often fall short.
Peptide therapy offers a fundamentally different approach: instead of masking pain, it supports the body's own repair mechanisms. And with proper veterinary oversight, it can be delivered safely and effectively.
How Long Companion Labs Is Different
We're not a supplement company. Long Companion Labs provides prescription-grade, pharmacy-compounded peptide therapy under the supervision of licensed veterinarians.
Here's what that means in practice:
Vet-Prescribed
Every treatment starts with a licensed veterinarian who evaluates your dog's specific health needs.
Pharmacy-Compounded
Medications are prepared by licensed 503A compounding pharmacies — not manufactured in unregulated facilities.
Weight-Based Dosing
Dogs range from 5 lb to 150+ lb. Flat dosing is inappropriate. Every prescription is calculated for your dog's specific weight, based on the pharmacokinetic data from published research.
Ongoing Monitoring
Your vet monitors your dog's progress and adjusts the protocol as needed. We track outcomes to build the evidence base the field needs.
The Senior Dog Longevity Guide
Why veterinarians are turning to BPC-157 peptide therapy for senior dogs — and what the research says it could do for yours.